A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma-Reference-Cited by-同舟云学术

A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma

Published:2017-02-23 Issue:15 Volume:8 Page:24250-24261
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Lim Kian-Huat¹,Langley Emma²,Gao Feng³,Luo Jingqin³,Li Lin¹,Meyer Gary²,Kim Phillip²,Singh Sharat²,Kushnir Vladamir M.⁴,Early Dayna S.⁴,Mullady Daniel K.⁴,Edmundowicz Steven A.⁵,Wani Sachin⁵,Murad Faris M.⁶,Cao Dengfeng⁷,Azar Riad R.⁴,Wang-Gillam Andrea¹

Affiliation:

1. Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA

2. Prometheus Laboratories Inc., San Diego, CA, USA

3. Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MO, USA

4. Division of Gastroenterology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA

5. Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

6. NorthShore University HealthSystem, Evanston, IL, USA

7. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma;Gastroenterology;2022-06

2. Phospho-Ser784-VCP Drives Resistance of Pancreatic Ductal Adenocarcinoma to Genotoxic Chemotherapies and Predicts the Chemo-Sensitizing Effect of VCP Inhibitor;Cancers;2021-10-11

3. Pancreatic Diseases;Clinical Molecular Diagnostics;2021

4. TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations;Journal of Clinical Investigation;2020-08-10

5. Biochemical diagnostics of pancreatic cancer - Present and future;Clinica Chimica Acta;2019-11